Online First

June 05, 2020

Correspondence response
Response to: ‘COVID-19 pandemic: an opportunity to assess the utility of telemedicine in patients with rheumatic diseases’ by Lopez-Medina et al
Free

Emanuele Bozzalla Cassione, Giovanni Zanframundo, Alessandro Biglia, Veronica Codullo, Carlomaurizio Montecucco, Lorenzo Cavagna

doi: 10.1136/annrheumdis-2020-218070

June 03, 2020

Correspondence
COVID-19 in rheumatology outpatient clinics: Dutch mirror image to Lombardy, Italy
Free

Sophie Benoy, Rene Traksel, Peter Verhaegh, Jasper Broen

doi: 10.1136/annrheumdis-2020-217765

June 01, 2020

Rheumatoid arthritis
Tapering towards DMARD-free remission in established rheumatoid arthritis: 2-year results of the TARA trial

Elise van Mulligen, Angelique E Weel, J M Hazes, Annette van der Helm-van Mil, Pascal Hendrik Pieter de Jong

doi: 10.1136/annrheumdis-2020-217485
Systemic sclerosis
PGC-1α regulates autophagy to promote fibroblast activation and tissue fibrosis

Yun Zhang, Lichong Shen, Honglin Zhu, Katja Dreissigacker, Diana Distler, Xiang Zhou, Andrea Hermina Györfi, Christina Bergmann, Xianyi Meng, Clara Dees, Thuong Trinh-Minh, Ingo Ludolph, Raymund Horch, Andreas Ramming, Georg Schett, Jörg H W Distler

doi: 10.1136/annrheumdis-2020-216963
Psoriatic arthritis
Mixed methods study of clinicians’ perspectives on barriers to implementation of treat to target in psoriatic arthritis

Emma Dures, Julie Taylor, Sasha Shepperd, Sandeep Mukherjee, Joanna Robson, Ivo Vlaev, Nicola Walsh, Laura C Coates

doi: 10.1136/annrheumdis-2020-217301

May 31, 2020

Correspondence
Patients with lupus with COVID-19: University of Michigan experience
Free

Beth Wallace, Laraine Washer, Wendy Marder, J Michelle Kahlenberg

doi: 10.1136/annrheumdis-2020-217794
Correspondence response
No advice to discontinue antirheumatic therapy for non-medical reasons in light of SARS-CoV-2. Response to: ‘Treatment adherence of patients with sytemic rheumatic diseases in COVID-19 pandemic’ by Fragoulis et al
Free

Hendrik Schulze-Koops, Klaus Krueger, Christof Specker

doi: 10.1136/annrheumdis-2020-217987
Correspondence
Treatment adherence of patients with systemic rheumatic diseases in COVID-19 pandemic
Free

George E Fragoulis, Gerasimos Evangelatos, Aikaterini Arida, Vasiliki-Kalliopi Bournia, Kalliopi Fragiadaki, Anastasios Karamanakos, Evrydiki Kravvariti, Katerina Laskari, Stylianos Panopoulos, Maria Pappa, Maria G Tektonidou, Petros P Sfikakis

doi: 10.1136/annrheumdis-2020-217935
Correspondence response
Patients with systemic lupus erythematosus using hydroxychloroquine or chloroquine develop severe COVID-19 at similar frequency as patients not on antimalarials: need to explore antithrombotic benefits for COVID-19 coagulopathy. Response to: ‘Clinical course of COVID-19 in patients with systemic lupus erythematosus under long-term treatment with hydroxychloroquine’ by Carbillon et al
Free

Maximilian F Konig, Milena Gianfrancesco, Jinoos Yazdany, Philip C Robinson

doi: 10.1136/annrheumdis-2020-217990
Correspondence response
Response to: ‘Patients with lupus with COVID-19: University of Michigan experience’ by Wallace et al
Free

Alexis Mathian, Zahir Amoura

doi: 10.1136/annrheumdis-2020-217910
Correspondence
Clinical course of COVID-19 in patients with systemic lupus erythematosus under long-term treatment with hydroxychloroquine
Free

Lionel Carbillon, Amélie Benbara, Jeremy Boujenah

doi: 10.1136/annrheumdis-2020-217847

May 29, 2020

Correspondence
Case series of acute arthritis during COVID-19 admission
Free

María-del-Carmen López-González, Maria Luisa Peral-Garrido, Irene Calabuig, Ernesto Tovar-Sugrañes, Vega Jovani, Pilar Bernabeu, Raquel García-Sevila, Jose-Manuel León-Ramírez, Oscar Moreno-Perez, Vicente Boix, Joan Gil, Esperanza Merino, Paloma Vela, Mariano Andrés

doi: 10.1136/annrheumdis-2020-217914
Correspondence response
The positive correlation between Porphyromonas gingivalis and Prevotella spp. Response to: ‘Comment on ‘Metagenome-wide association study of gut microbiome revealed novel aetiology of rheumatoid arthritis in the Japanese population’ by Kishikawa et al.’ by Kitamura et al
Free

Toshihiro Kishikawa, Yuichi Maeda, Takuro Nii, Yukinori Okada

doi: 10.1136/annrheumdis-2020-217897
Rheumatoid arthritis
Impact of rheumatoid arthritis on major cardiovascular events in patients with and without coronary artery disease

Brian Bridal Løgstrup, Kevin Kris Warnakula Olesen, Dzenan Masic, Christine Gyldenkerne, Pernille Gro Thrane, Torkell Ellingsen, Hans Erik Bøtker, Michael Maeng

doi: 10.1136/annrheumdis-2020-217154
Correspondence response
Response to: ‘Increasing incidence of autoantibody-negative RA is replicated and is partly explained by an aging population’ by Matthijssen et al
Free

Elena Myasoedova, John Davis, Eric L Matteson, Cynthia S Crowson

doi: 10.1136/annrheumdis-2020-217900
Correspondence response
Response to: Correspondence regarding research letter to the editor by Mathian et al, ‘Clinical course of coronavirus disease 2019 (COVID-19) in a series of 17 patients with systemic lupus under long-term treatment with hydroxychloroquine’’ by Nikpour et al
Free

Alexis Mathian, Zahir Amoura

doi: 10.1136/annrheumdis-2020-217875
Correspondence
Comment on: ‘Metagenome-wide association study of gut microbiome revealed novel aetiology of rheumatoid arthritis in the Japanese population’ by Kishikawa et al
Free

Kaori Kitamura, Hiroshi Shionoya, Kuniaki Terato, Suguru Suzuki, Richio Fukai, Shinichi Uda, Chiyuki Abe, Hiromitsu Takemori, Keita Nishimura, Hisashi Baba, Takaki Waritani, Kou Katayama

doi: 10.1136/annrheumdis-2020-217808
Correspondence response
Response to: ‘Case series of acute arthritis in COVID-19 admission’ by López-González et al
Free

Elizabeth R Graef, Jean W Liew, Alfred HJ Kim, Jeffrey A Sparks

doi: 10.1136/annrheumdis-2020-217989
Correspondence
Increasing incidence of autoantibody-negative RA is replicated and is partly explained by an aging population
Free

Xanthe M E Matthijssen, Tom W J Huizinga, Annette H M van der Helm-van Mil

doi: 10.1136/annrheumdis-2020-217609
Correspondence
Correspondence regarding research letter to the editor by Mathian et al, ‘Clinical course of coronavirus disease 2019 (COVID-19) in a series of 17 patients with systemic lupus under long-term treatment with hydroxychloroquine’
Free

Mandana Nikpour, Benjamin Teh, Ian P Wicks, Marc Pellegrini

doi: 10.1136/annrheumdis-2020-217827

May 28, 2020

Letter
Methotrexate reduces withdrawal rates of TNF inhibitors due to ineffectiveness in rheumatoid arthritis but only in patients who are seropositive

Mandy Greenwood, Muhammad Shipa, Su-Ann Yeoh, Euthalia Roussou, Dev Mukerjee, Michael R Ehrenstein

doi: 10.1136/annrheumdis-2020-217725
Correspondence response
Relationship between rheumatoid arthritis and interstitial lung disease is a ‘two-way street’. Response to: ‘Autoantibodies and interstitial lung disease in rheumatoid arthritis: towards a ‘mix-and-match’ approach’ by Alunno et al
Free

Raul Castellanos-Moreira, Sebastian Cruz Rodríguez-García, Isabel Haro, Raimon Sanmarti

doi: 10.1136/annrheumdis-2020-217432
Correspondence
‘Finding the right one’
Free

Abhishek Arvind Zanwar

doi: 10.1136/annrheumdis-2020-217731
Correspondence response
Response to: ‘Finding the right one’ by Zanwar
Free

Thomas Renson, Filip E Van den Bosch, Dirk Elewaut

doi: 10.1136/annrheumdis-2020-217856

May 27, 2020

Correspondence response
Response to: ‘Physician global assessment in systemic lupus erythematosus: can we rely on its reliability?’ by Chessa et al
Free

Anca Askanase, Shereen Oon, Molla Huq, Alicia Calderone, Eric F Morand, Mandana Nikpour, Cynthia Aranow

doi: 10.1136/annrheumdis-2020-217692
Correspondence response
Response to: ‘Associations of regular glucosamine use with all-cause and cause-specific mortality: causality assumptions need to be checked’ by Safiri and Mansournia
Free

Zhi-Hao Li, Qing-Mei Huang, Chen Mao

doi: 10.1136/annrheumdis-2020-217896
Correspondence
Associations of regular glucosamine use with all-cause and cause-specific mortality: causality assumptions need to be checked
Free

Saeid Safiri, Mohammad Ali Mansournia

doi: 10.1136/annrheumdis-2020-217732
Correspondence
Physician global assessment in systemic lupus erythematosus: can we rely on its reliability?
Free

Elisabetta Chessa, Matteo Piga, Laurent Arnaud

doi: 10.1136/annrheumdis-2020-217632
Letter
A pilot study of tofacitinib for refractory Behçet’s syndrome

Jinjing Liu, Yunxia Hou, Luxi Sun, Chaoran Li, Lu Li, Yan Zhao, Xiaofeng Zeng, Fengchun Zhang, Wenjie Zheng

doi: 10.1136/annrheumdis-2020-217307

May 26, 2020

Heroes and pillars of rheumatology
Eric Bywaters a life story: 1 June 1910 to 2 April 2003

David Isenberg

doi: 10.1136/annrheumdis-2020-217153

May 25, 2020

Correspondence response
Response to: ‘Are patients with systemic lupus erythematosus at increased risk for COVID-19?’ by Favalli et al
Free

Alexis Mathian, Zahir Amoura

doi: 10.1136/annrheumdis-2020-217859
Correspondence
Are patients with systemic lupus erythematosus at increased risk for COVID-19?
Free

Ennio Giulio Favalli, Maria Gerosa, Antonella Murgo, Roberto Caporali

doi: 10.1136/annrheumdis-2020-217787

May 24, 2020

Letter
Impact of delayed diagnoses at the time of COVID-19: increased rate of preventable bilateral blindness in giant cell arteritis
Free

Sara Monti, Paolo Delvino, Elisa Bellis, Alessandra Milanesi, Fabio Brandolino, Carlomaurizio Montecucco

doi: 10.1136/annrheumdis-2020-217915
Systemic lupus erythematosus
Long-term outcome of a randomised controlled trial comparing tacrolimus with mycophenolate mofetil as induction therapy for active lupus nephritis

Chi Chiu Mok, Ling Yin Ho, Shirley King Yee Ying, Man Chi Leung, Chi Hung To, Woon Leung Ng

doi: 10.1136/annrheumdis-2020-217178
Correspondence
Online management of rheumatoid arthritis during COVID-19 pandemic
Free

Yang Zhang, Jian Wang, Liang Zhao, Jun Xiao, Zhanjun Shi

doi: 10.1136/annrheumdis-2020-217548

May 23, 2020

Correspondence response
Response to: ‘Antimalarial use and arrhythmias in COVID-19 and rheumatic patients: a matter of dose and inflammation?’ by Erre et al
Free

Elizabeth R Graef, Jean W Liew, Alfred HJ Kim, Jeffrey A Sparks

doi: 10.1136/annrheumdis-2020-217923
Correspondence
COVID-19 pneumonia in a large cohort of patients treated with biological and targeted synthetic antirheumatic drugs
Free

Edoardo Conticini, Elena Bargagli, Marco Bardelli, Giuseppe Domenico Rana, Caterina Baldi, Paolo Cameli, Stefano Gentileschi, David Bennett, Paolo Falsetti, Nicola Lanzarone, Francesca Bellisai, Cristiana Barreca, Roberto D'Alessandro, Luca Cantarini, Bruno Frediani

doi: 10.1136/annrheumdis-2020-217681
Letter
Anti-inflammatory therapy may ameliorate the clinical picture of COVID-19
Free

Haralampos M Moutsopoulos

doi: 10.1136/annrheumdis-2020-217562
Correspondence
What is the true incidence of COVID-19 in patients with rheumatic diseases?
Free

Ennio Giulio Favalli, Francesca Ingegnoli, Rolando Cimaz, Roberto Caporali

doi: 10.1136/annrheumdis-2020-217615
Correspondence response
Response to ‘To consider or not antimalarials as a prophylactic intervention in the SARS-CoV-2 (Covid-19) pandemic’ by Parperis
Free

Francesca Romana Spinelli, Fulvia Ceccarelli, Manuela Di Franco, Fabrizio Conti

doi: 10.1136/annrheumdis-2020-217634
Correspondence
Rituximab for granulomatosis with polyangiitis in the pandemic of covid-19: lessons from a case with severe pneumonia
Free

Philippe Guilpain, Clément Le Bihan, Vincent Foulongne, Patrice Taourel, Nathalie Pansu, Alexandre Thibault Jacques MARIA, Boris Jung, Romaric Larcher, Kada Klouche, Vincent Le Moing

doi: 10.1136/annrheumdis-2020-217549
Correspondence
Hydroxychloroquine reduces the risk of covid-19 in patients with rheumatic diseases: myth or reality?
Free

Wenhui Xie, Yu Wang, Zhuoli Zhang

doi: 10.1136/annrheumdis-2020-217556
Correspondence
No evidence so far on the protective effect of hydroxychloroquine to prevent COVID-19: response to the comment by Joob and Wiwanitkit
Free

Vasco C. Romão, Ana Rita Cruz-Machado, João Eurico Fonseca

doi: 10.1136/annrheumdis-2020-217665
Correspondence response
The conundrum of COVID-19 treatment targets: the close correlation with rheumatology. Response to: ‘Management of rheumatic diseases in the time of covid-19 pandemic: perspectives of rheumatology pracitioners from India’ by Gupta et al and ‘Antirheumatic agents in covid-19: is IL-6 the right target?’ by Capeechi et al
Free

Sara Monti, Carlomaurizio Montecucco

doi: 10.1136/annrheumdis-2020-217545
Correspondence
Coronavirus disease 19 (Covid-19) and non-steroidal anti-inflammatory drugs (NSAID)
Free

Alessandro Giollo, Giovanni Adami, Davide Gatti, Luca Idolazzi, Maurizio Rossini

doi: 10.1136/annrheumdis-2020-217598
Letter
COVID-19 infection in a northern-Italian cohort of systemic lupus erythematosus assessed by telemedicine
Free

Emanuele Bozzalla Cassione, Giovanni Zanframundo, Alessandro Biglia, Veronica Codullo, Carlomaurizio Montecucco, Lorenzo Cavagna

doi: 10.1136/annrheumdis-2020-217717

May 22, 2020

Correspondence
To consider or not antimalarials as a prophylactic intervention in the SARS-CoV-2 (COVID-19) pandemic
Free

Konstantinos Parperis

doi: 10.1136/annrheumdis-2020-217557
Correspondence
SLE patients are not immune to covid-19: importance of sending the right message across
Free

Mohit Goyal

doi: 10.1136/annrheumdis-2020-217658
Correspondence
Patients with lupus are not protected from COVID-19
Free

Amr H Sawalha

doi: 10.1136/annrheumdis-2020-217656
Correspondence response
Response to: ‘Patients with lupus are not protected from COVID-19: a comment’ by Sawalha, ‘No evidence so far on the protective effect of hydroxycloroquin to prevent COVID-19: response to the Comment by Joob and Wiwanitkit’ by Romão et al and ‘SLE patients are not immune to COVID-19: importance of sending the right message across’ by Goyal
Free

Beuy Joob, Viroj Wiwanitkit

doi: 10.1136/annrheumdis-2020-217695

Log in using your username and password

Main menu

Log in using your username and password

You are here

Online First

June 05, 2020

June 03, 2020

June 01, 2020

May 31, 2020

May 29, 2020

May 28, 2020

May 27, 2020

May 26, 2020

May 25, 2020

May 24, 2020

May 23, 2020

May 22, 2020

Pages